STEROIDAL DRUGS IN ENDOMETRIOSIS

Area of Science:

• Reproductive Endocrinology
• Gynecology
• Pharmacology

Background:

• Endometriosis is managed with progestins like medroxyprogesterone acetate (MPA), danazol, and gestrinone.
• These drugs exhibit progestin-like effects on the endometrium, but ectopic tissue shows limited response.
• Therapeutic effects may stem from indirect actions on the hypothalamic-pituitary-ovarian axis.

Purpose of the Study:

• To compare the clinical efficacy and side effects of danazol and high-dose MPA in endometriosis management.
• To evaluate the impact of these hormonal therapies on fertility outcomes in infertile patients with endometriosis.

Main Methods:

• A 6-month randomized trial comparing danazol, MPA, and placebo for endometriosis.
• Assessment of symptom relief, lesion disappearance, and androgenic/metabolic side effects.
• Long-term follow-up to determine cumulative pregnancy rates in infertile patients.

Main Results:

• Danazol and MPA demonstrated equal clinical efficacy in treating endometriosis symptoms and lesions.
• Danazol therapy was associated with more androgenic and metabolic side effects compared to MPA.
• No significant difference in cumulative pregnancy rates was observed between danazol, MPA, and placebo groups; hormonal therapy delayed conception.

Conclusions:

• Both danazol and MPA are effective for endometriosis, with indirect hormonal suppression being a primary mechanism.
• Danazol and MPA are not recommended as first-line treatments for endometriosis-associated infertility.
• Further research into managing infertility in endometriosis patients is warranted.